Show
Sort by
-
Effect of screening for Neisseria gonorrhoeae and Chlamydia trachomatis on incidence of these infections in men who have sex with men and transgender women taking HIV pre-exposure prophylaxis (the Gonoscreen study): results from a randomised, multicentre, controlled trial
-
Efficacy, durability, and tolerability of bictegravir/emtricitabine/tenofovir alafenamide for the treatment of HIV in a real‐world setting in Belgium
-
- Conference Paper
- C3
- open access
Linking inducible HIV-1 reservoir to rebound after treatment interruption
-
Does screening for<i>Neisseria gonorrhoeae</i>and<i>Chlamydia trachomatis</i>affect the incidence of these infections in men who have sex with men taking HIV pre-exposure prophylaxis (PrEP)Results from a randomized, multicentre controlled trial (the Gonoscreen study)
(2023) -
- Journal Article
- A1
- open access
Impact of COVID-19 on the Belgian HIV epidemic : slowdown of HIV transmission and testing and adaptation of care
-
Impact of PrEP on a STI clinic in a Belgian context : a provider’s perspective
-
Clinical characteristics and outcomes of COVID‐19 in people living with HIV in Belgium : a multicenter, retrospective cohort
-
Quality of life in people living with HIV : an exploratory cross-sectional survey in Belgium
-
- Journal Article
- A1
- open access
Week 48 resistance analyses of the once-daily, single-tablet regimen darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in adults living with HIV-1 from the Phase III Randomized AMBER and EMERALD Trials
-
Population pharmacokinetics and pharmacogenetics of ritonavir-boosted darunavir in the presence of raltegravir or tenofovir disoproxil fumarate/emtricitabine in HIV-infected adults and the relationship with virological response : a sub-study of the NEAT001/ANRS143 randomized trial
-
- Journal Article
- A1
- open access
Rapid viral rebound after analytical treatment interruption in patients with very small HIV reservoir and minimal on-going viral transcription
-
- Journal Article
- A1
- open access
Incidence rate, predictors and outcomes of interruption of HIV care : nationwide results from the Belgian HIV cohort
-
Uptake and effectiveness of two-drug compared with three-drug antiretroviral regimens among HIV-positive individuals in Europe
-
Analytical treatment interruption (ATI) in patients with very small HIV reservoir
-
- Journal Article
- A1
- open access
Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1